[Federal Register Volume 88, Number 187 (Thursday, September 28, 2023)]
[Notices]
[Pages 66863-66864]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21156]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Sickle Cell Disease 
Advisory Committee.
    The meeting will be held as a virtual meeting and will be open to 
the public as indicated below. Individuals who plan to view the virtual 
meeting and need special assistance or other reasonable accommodations 
to view the meeting, should notify the Contact Person listed below in 
advance of the meeting. The meeting can be accessed from the NIH 
Videocast at the following link: https://videocast.nih.gov/.

    Name of Committee: Sickle Cell Disease Advisory Committee.
    Date: January 29, 2024.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: NHLBI Sickle Cell Disease Program Updates.
    Place: National Institutes of Health, Rockledge Centre I, 6705 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Telephone Access: +1 669 254 5252 (Meeting ID 160 763 2658). 
Virtual Access: https://nih.zoomgov.com/j/1607632658 (Meeting ID: 
160 763 2658).
    Contact Person: Julie A. Panepinto, MD, MSPH, SCDAC Executive 
Secretary, Director, Division of Blood Diseases and Resources, 
National Institutes of Health, National Heart, Lung, and Blood 
Institute, 6701 Rockledge Drive, Suite 9166, Bethesda, MD 20892, 
301-435-0080, <a href="/cdn-cgi/l/email-protection#81cfc9cdc3c8c5c3c5d3c6f3e0eff5d3e4f2eef4f3e2e4c1efe9ede3e8afefe8e9afe6eef7"><span class="__cf_email__" data-cfemail="1e5056525c575a5c5a4c596c7f706a4c7b6d716b6c7d7b5e7076727c773070777630797168">[email protected]</span></a>.

    Any member of the public interested in presenting oral comments 
to the committee may notify the Contact Person listed on this notice 
at least 10 days in advance of the meeting. Interested individuals 
and representatives of organizations may submit a letter of intent, 
a brief description of the organization represented, and a short 
description of the oral presentation. Only one representative of an 
organization may be allowed to present oral comments and if accepted 
by the committee, presentations may be limited to five minutes. Both 
printed and electronic copies are requested for the record. In 
addition, any interested person may file written comments with the 
committee by forwarding their statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: https://www.nhlbi.nih.gov/advisory-and-peer-review-committees/nhlbi-sickle-cell-disease-advisory-committee, where an agenda and 
any additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)


[[Page 66864]]


    Dated: September 22, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-21156 Filed 9-27-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>